Opiod-Induced Constipation: Update on Prevention & Management– Opioids are increasingly prescribed to treat chronic cancer and noncancer pain. Opioid-induced constipation (OIC) is one of the most common and troublesome adverse events associated with opioids, impacting the majority of patients being treated for chronic pain. In addition to the clinical consequences, OIC is also associated with diminished quality of life, compromised pain management, and increased use of healthcare resources. For many, laxatives remain the treatment of choice in preventing and managing OIC, but these agents are associated with significant limitations and risks. More recent advancements have led to the development of a more targeted approach that specifically counteracts the effects of opioids in the gastrointestinal tract. As the role of health-system pharmacists in managing patients with chronic pain grows within the multidisciplinary team, it is imperative that pharmacists improve their competence in the prevention and treatment of OIC. This can include utilizing effective prevention st rategies, recognizing the early signs of OIC, and selecting the optimal approach to treat OIC based on patient-specific factors. This program provides an overview of the burden and pathophysiology of OIC and offers practical solutions in the prevention and treatment of OIC through case-based discussions.
Describe the pathophysiology of opioid-induced constipation.
List evidence-based approaches to minimize the risk of OIC in patients receiving opioids.
Evaluate the use of laxatives versus targeted therapy to manage opioid-induced constipation.
1.0 Free CEUs for Pharmacists